AnaptysBio Inc (ANAB)
NASDAQ:ANAB
Top Page
AnaptysBio
(NASDAQ:ANAB)
Select Model
Select Model
Rating:53Neutral
Price Target:
$71.00
▲(3.30% Upside)
Action:ReiteratedDate:03/28/26
The score is held back primarily by weak and volatile financial quality (negative gross profit, historical losses, and past leverage volatility) despite a clear 2025 improvement in revenue and cash flow. Technicals are moderately supportive, corporate actions add a positive catalyst, but valuation remains challenging due to negative earnings and no dividend.
Positive Factors
Strategic spin-off of First Tracks Bio
Spinning out First Tracks creates two focused entities: Anaptys shifts to royalty management while First Tracks inherits development risk and R&D capital. The $180M launch fund and dedicated runway materially de-risks Anaptys’ cash burn exposure and clarifies capital allocation for durable shareholder value.
Negative Factors
Negative gross profit across years
Persistent negative gross profit indicates core unit economics do not cover direct costs, threatening sustainable margins. Even with revenue gains, inability to generate positive gross margin requires structural cost or pricing changes to deliver durable profitability and protect cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic spin-off of First Tracks Bio
Spinning out First Tracks creates two focused entities: Anaptys shifts to royalty management while First Tracks inherits development risk and R&D capital. The $180M launch fund and dedicated runway materially de-risks Anaptys’ cash burn exposure and clarifies capital allocation for durable shareholder value.
Read all positive factors
AnaptysBio (ANAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.02B
Dividend YieldN/A
Average Volume (3M)624.61K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue Growth196.42%
EPS Growth53.92%
CountryUS
Employees136
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.58
Shares Outstanding28,748,255
10 Day Avg. Volume572,411
30 Day Avg. Volume624,611
Financial Highlights & Ratios
PEG Ratio1.12
Price to Book (P/B)36.21
Price to Sales (P/S)5.74
P/FCF Ratio68.70
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue8.65
Enterprise Value/Gross Profit8.74
Enterprise Value/Ebitda30.39
Forecast
1Y Price Target
$83.22Price Target Upside21.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.94
Revenue Forecast (FY)$111.27M
AnaptysBio Business Overview & Revenue Model
Company Description
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 recepto...
How the Company Makes Money
AnaptysBio makes money primarily through collaboration and licensing arrangements rather than product sales (its programs are largely in clinical development). Under these types of deals, revenue is typically generated from (1) upfront payments re...
AnaptysBio Financial Statement Overview
Summary
Income Statement
48
Neutral
Balance Sheet
40
Negative
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 234.60M | 91.28M | 17.16M | 10.29M | 63.17M |
| Gross Profit | 232.18M | -72.56M | -115.13M | -78.51M | -35.32M |
| EBITDA | 50.32M | -92.74M | -156.42M | -105.26M | -55.71M |
| Net Income | -13.23M | -145.23M | -163.62M | -128.72M | -57.80M |
Balance Sheet | |||||
| Total Assets | 364.39M | 483.83M | 452.39M | 610.38M | 643.07M |
| Cash, Cash Equivalents and Short-Term Investments | 311.64M | 385.37M | 390.90M | 441.24M | 548.10M |
| Total Debt | 14.11M | 369.46M | 17.81M | 19.45M | 20.95M |
| Total Liabilities | 327.19M | 412.97M | 364.29M | 348.28M | 286.64M |
| Stockholders Equity | 37.21M | 70.87M | 88.10M | 262.10M | 356.43M |
Cash Flow | |||||
| Free Cash Flow | 19.61M | -135.69M | -121.61M | -73.95M | -47.29M |
| Operating Cash Flow | 19.70M | -135.34M | -120.80M | -73.59M | -45.92M |
| Investing Cash Flow | 228.03M | 95.40M | 144.75M | -394.85M | 38.84M |
| Financing Cash Flow | -132.61M | 127.05M | -59.30M | 44.02M | 252.30M |
AnaptysBio Technical Analysis
Positive
68.73
Price Trends
58.18
Positive
51.66
Positive
39.13
Positive
Market Momentum
2.32
Negative
63.73
Neutral
90.67
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Positive. The current price of 68.73 is above the 20-day moving average (MA) of 63.01, above the 50-day MA of 58.18, and above the 200-day MA of 39.13, indicating a bullish trend. The MACD of 2.32 indicates Negative momentum. The RSI at 63.73 is Neutral, neither overbought nor oversold. The STOCH value of 90.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANAB.
AnaptysBio Risk Analysis
AnaptysBio disclosed 42 risk factors in its most recent earnings report. AnaptysBio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AnaptysBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $6.07B | -39.12 | -20.02% | ― | ― | 12.45% | |
57 Neutral | $220.93M | 8.71 | 14.25% | ― | 37798.31% | ― | |
54 Neutral | $730.57M | -5.60 | -1065.47% | ― | 96.83% | -61.92% | |
53 Neutral | $2.02B | -101.81 | 1813.84% | ― | 196.42% | 53.92% | |
52 Neutral | $931.05M | -12.74 | -43.61% | ― | -100.00% | -28.79% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $1.40B | -13.39 | -42.90% | ― | ― | 17.23% |
* Healthcare Sector Average
ANAB
AnaptysBio
68.73
50.87
284.83%
MGTX
Meiragtx Holdings
9.63
4.15
75.73%
KROS
Keros Therapeutics
11.15
-1.59
-12.48%
CMPX
Compass Therapeutics
5.20
3.48
202.33%
OLMA
Olema Pharmaceuticals
15.93
11.87
292.36%
TERN
Terns Pharmaceuticals
52.61
50.30
2177.49%
AnaptysBio Corporate Events
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing
AnaptysBio Advances First Tracks Spin-Off and Governance Changes
Positive
Mar 27, 2026
AnaptysBio, Inc. is a biotechnology company that is spinning out First Tracks Biotherapeutics as a separate, clinical-stage biotech focused on next-generation antibody therapeutics targeting immune pathways in autoimmune and inflammatory diseases....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.